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Abstract
Background—Orotic aciduria in the presence of hyperammonemia is a key indicator for a defect 
in the urea cycle, specifically ornithine transcarbamylase (OTC) deficiency. Current newborn 
screening (NBS) protocols can detect several defects of the urea cycle, but screening for OTC 
deficiency remains a challenge due to the lack of a suitable assay. The purpose of this study was to 
develop a high-throughput assay to measure orotic acid in dried blood spot (DBS) specimens as an 
indicator for urea cycle dysfunction, which can be readily incorporated into routine NBS.
Methods—Orotic acid was extracted from DBS punches and analyzed using flow-injection 
analysis tandem mass spectrometry (FIA–MS/MS) with negative-mode ionization, requiring <2 
min/sample run time. This method was then multiplexed into a conventional newborn screening 
assay for analysis of amino acids, acylcarnitines, and orotic acid.
Results—We describe 2 assays which can quantify orotic acid in DBS: a stand-alone method and 
a combined method for analysis of orotic acid, amino acids, and acylcarnitines. Both methods 
demonstrated orotic acid recovery of 75–85% at multiple levels of enrichment. Precision was also 
comparable to traditional FIA–MS/MS methods. Analysis of residual presumptively normal NBS 
specimens demonstrated a 5:1 signal to noise ratio and the average concentration of orotic acid 
was approximately 1.2 μmol/l. The concentration of amino acids and acylcarnitines as measured 
by the combined method showed no significant differences when compared to the conventional 
newborn screening assay. In addition, retrospective analysis of confirmed patients and 
presumptively normal newborn screening specimens suggests potential for the methods to identify 
patients with OTC deficiency, as well as other urea cycle defects.
Conclusion—The assays described here quantify orotic acid in DBS using a simple extraction 
and FIA–MS/MS analysis procedures that can be implemented into current NBS protocols.
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1. Introduction
A principal function of the urea cycle is to convert nitrogen waste, accumulated from either 
amino acid metabolism or intestinal bacteria, into urea, which can be safely excreted from 
the body. There are five catalyzed reactions in the urea cycle and defects of any step lead to 
the accumulation of ammonia with subsequent damage to the central nervous system [1]. In 
the most severe urea cycle defects, newborns will appear healthy during the first 24 h after 
birth, but will decompensate within days, develop vomiting and lethargy, worsening to coma 
and eventually death [1]. Early detection and treatment during the newborn period is critical 
to the prevention of these severe adverse outcomes [2].
The current US recommended uniform newborn screening (NBS) panel includes two urea 
cycle defects; argininosuccinic acid synthase (ASS) deficiency and argininosuccinic acid 
lyase (ASL) deficiency [3]. One of the most common and severe defect of the urea cycle, 
ornithine transcarbamylase (OTC) deficiency, was considered for inclusion in the panel, but 
it did not meet the assigned evaluation criteria, due to the lack of a screening test that had 
been validated in the general newborn population [4]. OTC deficiency, an X-linked disorder, 
has a wide range of clinical variability and can present in a severe neonatal-onset form that 
is life threatening within the first few days after birth or as a late-onset, typically milder, 
form of the disease. Female carriers can also experience symptoms related to increased 
ammonia levels [1]. The laboratory indications for OTC deficiency are elevated 
concentrations of glutamine and ammonia, low citrulline, and elevated excretion of orotic 
acid in the urine [2]. NBS laboratories have attempted to use glutamine and citrul-line to 
identify infants at risk for OTC deficiency, but have had limited success [5,6].
Orotic acid is an excellent marker for OTC deficiency. Orotic acid increases in urea cycle 
disorders due to the accumulation of carbamoyl phosphate when there is a mismatch 
between the fluxes through carbamoyl phosphate synthetase and the urea cycle steps. 
Carbamoyl phosphate enters the pyrimidine nucleotide synthesis pathway leading to 
markedly increased concentrations of orotic acid [7]. Orotic acid can be quantified in urine 
or plasma using liquid chromatography–tandem mass spectrometry (LC–MS/MS) methods, 
which combine an easy extraction, not requiring derivatization, with a short analysis time 
per sample [8,9]. In 2010, D’Apolite et al., published a method for quantification of orotic 
acid in urine, plasma, and dried-blood spots using a hydrophilic interaction LC–MS/MS 
method [10,11]. This was the first report of using DBS specimens to measure orotic acid 
concentrations for the detection of urea cycle defects. However, shorter analysis times per 
sample (<2 min) using flow-injection analysis tandem mass spectrometry (FIA–MS/MS) 
would be advantageous for integration of OTC deficiency into the current NBS assays.
A recent publication by Janzen et al., stated that orotic acid can be measured simultaneously 
with amino acids and acylcarnitines extracted from DBS using FIA–MS/MS [12]. This 
present study provides the detailed FIA–MS/MS method and data demonstrating an accurate 
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quantification of orotic acid along with the traditional set of amino acid and acylcarnitine 
species. In addition, orotic acid was quantified in 1514 presumptively normal newborn DBS 
specimens and in 7 patients with confirmed OTC deficiency or other urea cycle defects.
2. Materials and methods
2.1. Dried-blood specimens
A protocol for use of residual, de-identified DBS specimens was approved by the Health 
Sciences Institutional Review Board (IRB) at the University of Wisconsin. All residual, 
presumptively normal, dried blood spot specimens were collected between 24 and 96 h after 
birth and were stored at 4 °C after routine NBS analysis. In addition, DBS specimens from 
seven patients diagnosed with either OTC deficiency or other urea cycle disorders were 
obtained from the California State Newborn Screening Laboratory and the Wisconsin State 
Newborn Screening Laboratory. These specimens were de-identified, according to IRB 
approved protocol, and used to evaluate the clinical performance of the assay. Samples were 
stored at −20 °C prior to analysis of orotic acid.
2.2. Reagents and standards
Orotic acid, amino acid, and acylcarnitine standards and ammonium hydroxide were 
purchased from Sigma-Aldrich. The isotopically labeled internal standards for amino acids, 
acylcarnitines, and orotic acid were purchased from Cambridge Isotope Laboratories, Inc. 
Acetonitrile and methanol HPLC–MS grade solvents were from J.T. Baker. Grade 903 filter 
paper for DBS preparation was from Whatman GmbH.
2.3. Quality control materials
Quality control materials for orotic acid were prepared by enriching whole blood from 
presumptively normal adult donors with varying amounts of orotic acid. Whole blood 
adjusted to a 50% hematocrit was enriched with 1 and 10 μmol/l orotic acid, and was spotted 
onto filter paper to prepare the low-enrichment and high-enrichment quality control 
materials, respectively. Additional quality control materials with enrichments ranging from 
0.25 to 40 μmol/l of orotic acid were also prepared and used to assess the method’s linearity 
and limit of quantification. The unenriched and enriched whole blood pools were dispensed 
onto filter paper, dried overnight under ambient conditions, and stored at −20 °C in zip-
closure plastic bags containing desiccant packets. Quality control materials for amino acid 
and acylcarnitine analysis were obtained from the Newborn Screening Quality Assurance 
Program at the Centers for Disease Control and Prevention (CDC).
2.4. Stand-alone method for quantification of orotic acid
Orotic acid was extracted from DBS using 80:20 acetonitrile/water containing 0.5 μmol/l 
[1,3-15N2] orotic acid. To prepare the extraction solvent, 10 mg of [1,3-15N2] orotic acid was 
dissolved in 10 ml of 1 mol/l NaOH to create a 1 mg/ml stock solution, which was stable for 
3 days at 20 °C based upon reproducible peak areas for [1,3-15N2] orotic acid in dilutions 
made on days 1 to 3. A working internal standard solution of 0.5 μmol/l [1,3-15N2] orotic 
acid was prepared in 80:20 acetonitrile/water. A 3 mm (1/8th inch) punch from the DBS was 
placed into a 96-well round bottom polypropylene plate. One hundred fifty micro-liters of 
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working internal standard solution were added to each punch followed by shaking at room 
temperature for 30 min. Finally, the extraction solution was transferred to a clean 96-well 
plate for FIA–MS/MS analysis.
Orotic acid was analyzed using an AB Sciex API 4000 tandem mass spectrometer with a 
TurboV electrospray ionization source. All data acquisition and processing was performed 
using Analyst 1.5.2 software (AB Sciex). The API 4000 (AB Sciex) tandem mass 
spectrometer was operated in negative-ionization mode with the following parameters: ion 
spray voltage at −4500 V, entrance potential at −10 V, declustering potential at −48 V, 
collision energy at −14 V, and collision cell exit potential at −9 V. The mobile phase of 80:20 
acetonitrile/water containing 0.02% ammonium hydroxide (v/v) flowed at a rate of 0.08 
ml/min and the analysis time per sample was 1.2 min. The injected sample volume was 10 
μl. Orotic acid and its internal standard was analyzed using the following multiple reaction 
monitoring (MRM) pairs for the neutral loss of carbon dioxide: 154.9 → 110.9 and 156.9 → 
112.9 (Fig. 1), respectively. Orotic acid concentrations were determined using the following 
calculation: (analyte peak area divided by internal standard peak area) multiplied by the 
internal standard concentration (0.5 μmol/l) multiplied by the dilution of DBS punch blood 
into the extraction solution.
2.5. Combined method for quantification of amino acids, acylcarnitine species, and orotic 
acid
A routine, non-derivatized FIA–MS/MS method for analysis of amino acid and acylcarnitine 
species was modified to include orotic acid. All analytes were extracted from 3 mm (1/8th 
inch) DBS by addition of 100 μl of methanol containing internal standards for amino acids, 
acylcarnitines, and orotic acid followed by shaking at room temperature for 30 min. The AB 
Sciex API 4000 tandem mass spectrometer with a TurboV electrospray ionization source 
was operated in both positive-and negative-ionization modes. The mobile phase of 80:20 
acetonitrile/water was devoid of both formic acid and ammonium hydroxide and flowed at a 
rate of 0.06 ml/min for the first 30 s and then slowed to 0.03 ml/min for the remaining 1 min 
of the run. Amino acids, acylcarnitines, and orotic acid were quantified using ChemoView 
2.0.2 software (AB Sciex).
3. Results
3.1. Validation of stand-alone method for orotic acid
Method precision for orotic acid was evaluated by analysis of three quality control materials 
(un-enriched, 1 μmol/l low enrichment, and 10 μmol/l high enrichment) on five different 
days (with n = 5 for each day). The inter-day CV for all three quality control enrichments 
was <15%. The limit of quantification (LOQ) for orotic acid was determined (by the y-
intercept of the standard curve) to be 1 μmol/l, with a CV <15%. Analysis of unenriched 
DBS specimens demonstrated a 5:1 signal-to-noise ratio for orotic acid with an approximate 
concentration of 1.20 μmol/l. Apparent recovery was measured by comparison of the 
observed orotic acid concentrations to DBS quality control materials with two levels of 
enrichment (1 and 10 μmol/l) (Table 2). The slope and y-axis intercept of the standard curve, 
ranging from 5 to 40 μmol/l, were 0.73 and 1.02, respectively, with a coefficient of 
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correlation (R2) of >0.999. Therefore, orotic acid recovery was estimated to be 
approximately 75% based upon both evaluations of quality control materials.
3.2. Quantification of orotic acid in presumptively normal NBS specimens and in seven 
patients with confirmed urea cycle defects
NBS specimens from 1514 presumptively normal newborns and 7 specimens from patients 
with urea cycle defects were analyzed for orotic acid using the stand-alone method described 
above. The orotic acid concentrations within the normal population ranged from 0.59 to 2.61 
μmol/l, with an average concentration of 1.20 ± 0.23 μmol/l (median = 1.18 μmol/l; 1st–99th 
percentile 0.72–1.84 μmol/l) (Fig. 2).
Table 1 shows orotic acid concentrations from 7 patients with confirmed urea cycle 
disorders. Citrulline values were obtained through the original routine NBS results. Patients 
one and 2 are both males with OTC deficiency. The specimens were collected at 32 and 52 h 
after birth and routine NBS revealed below-normal citrulline concentrations (5 μmol/l) for 
both specimens. The orotic acid concentrations using the described method were 11.0 and 
21.8 μmol/l for each sample, respectively. Patients 3 and 4 both have argininosuccinic acid 
synthetase deficiency, which is characterized by elevated citrulline concentrations (2796 and 
1205 μmol/l, respectively). These specimens were collected at 18 and 4 days after birth and 
the orotic acid concentrations were 71.1 and 38.3 μmol/l, respectively. Patients 5, 6, and 7 
have argininosuccinic acid lyase deficiency, which is characterized by accumulation of 
argininosuccinic acid and increased citrulline levels (130, 199, and 107 μmol/l, respectively). 
The orotic acid concentrations in these 3 samples ranged from 2.58 to 10.6 μmol/l.
3.3. Validation of combined method for amino acid, acylcarnitine, and orotic acid analysis
Precision of orotic acid quantification using the combined method was determined by 
analyzing three quality control materials (unenriched, 1 μmol/l low enrichment, and 10 
μmol/l high enrichment) over 5 different days (with N = 10 each day). The inter-day CV for 
the high enrichment was <10%, however the low enrichment and unenriched specimens both 
had <25% CV. Recovery was determined to be approximately 85% by comparing the 
observed orotic acid concentration to the low and high enrichment values of the quality 
control material (Table 2). Five hundred and sixteen presumptively normal newborn 
screening specimens collected at 24–96 h after birth were analyzed for orotic acid. The 
concentrations ranged from 0.38 to 3.36 μmol/l, with an average concentration of 1.29 
± 0.45 μmol/l (median = 1.23 μmol/l; 1st–99th percentile 0.50–2.85 μmol/l) (Fig. 2).
Precision of the combined method for amino acid and acylcarnitine species was determined 
by analyzing three quality control materials (un-enriched, low enrichment, and high 
enrichment) over 5 different days (with n = 10 each day). The average inter-day CVs for 
both low and high enrichments of amino acids and acylcarnitine species were <10% and 
<15%, respectively. The average inter-day CVs for unenriched amino acids and acylcarnitine 
species were M <10% and <25%, respectively.
To demonstrate a similarity between the combined method and the current, routine, non-
derivatized assay for amino acid and acylcarnitine analysis, the same 636 presumptively 
normal newborn screening specimens were analyzed by both methods and the results were 
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compared. Fig. 3 shows a box–whisker plot for each analyte analyzed by the two methods. 
The majority of analytes had a <15% difference in normal patient means between the 
methods, with the exception of C3DC/C4OH, C4DC/C5OH, tyrosine, and citrulline. 
Overall, no significant measurement differences were observed.
4. Discussion
The clinical presentation of hyperammonemia is common to the majority of urea cycle 
disorders and treatment prior to the onset of symptoms is critical to the prevention of 
devastating outcomes, including permanent neurological injury [1,2]. Most NBS programs 
have implemented testing for two urea cycle defects (argininosuccinic acid synthetase 
deficiency and argininosuccinic acid lyase deficiency) and studies have suggested favorable 
clinical outcomes associated with early diagnosis [13,14]. NBS for the most common urea 
cycle disorder, OTC deficiency, however, has not been uniformly implemented largely due to 
the lack of a high-throughput assay.
Elevated orotic acid is a key diagnostic finding in patients with OTC deficiency. Advances in 
LC–MS/MS have enabled rapid detection of orotic acid in plasma and urine without the use 
of derivatizing agents and long run times associated with other analytical methods. Detection 
of orotic acid in DBS was demonstrated using a hydrophilic interaction LC–MS/MS method 
with a run time of 5 min/sample [11]. Although this method identified patients with OTC 
deficiency, shorter run times are necessary for a high-throughput NBS laboratory [10].
The objective of our study was to develop a FIA–MS/MS method that incorporates orotic 
acid into routine newborn screening assays. To accomplish this goal, a FIA–MS/MS stand-
alone method for orotic acid was first developed as a benchmark to which a combined FIA–
MS/MS method (including amino acids, acylcarnitines, and orotic acid) could be compared. 
Using the stand-alone method, orotic acid was extracted from DBS and analyzed by FIA–
MS/MS requiring approximately 1 min/sample. Validation parameters such as precision and 
recovery were comparable to previous reports of analytes measured by FIA–MS/MS [15–
18]. Linearity was demonstrated up to a 40 μmol/l enrichment of orotic acid in DBS. 
Although patient samples may have orotic acid values greater than the highest concentration 
tested here (40 μmol/l), for NBS purposes this linear range encompasses both normal and 
significantly elevated orotic acid values. DBS from presumptively normal newborns had an 
average orotic acid concentration of 1.20 ± 0.23 μmol/l, which was similar to previous 
reports [10,12]. Analysis of DBS from two patients with OTC deficiency and five patients 
with other distal urea cycle disorders (argininosuccinic acid synthetase deficiency and 
argininosuccinic acid lyase deficiency) showed a significant increase in orotic acid 
concentration, greater than the 99th percentile above the presumed normal average.
Next, we chose to incorporate orotic acid into our current NBS assay for amino acids and 
acylcarnitines, which uses a methanol extraction and FIA–MS/MS (<2 min run time); amino 
acids and acylcarnitines were quantified using positive ion mode scans (neutral loss of 46 Da 
and precursor scans of m/z 85, respectively) while orotic acid and its internal standard were 
quantified using negative ionization mode MRMs. Switching the mass spectrometer between 
positive and negative ionization modes during analysis of one sample [19,20] can be an 
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effective way to quantify multiple metabolites when some of the metabolites (amino acids 
and acylcarnitines) readily generate positive precursor ions while others (orotic acid) readily 
generate negative precursor ions; however consideration must be given to the ability to 
quantify all analytes accurately. A comparison of amino acid and acylcarnitine quantification 
with and without polarity switching indicated that including the negative ionization mode 
did not significantly change the results. For implementation however, minor adjustments to 
analyte cutoffs may be necessary. In addition, the orotic acid concentrations resulting from 
polarity switching analyses were not significantly different from the results of the FIA–
MS/MS stand-alone method, although the standard deviation was larger, which is likely a 
result of the decreased number of scans obtained by the mass spectrometer. Given the degree 
of orotic acid elevation in patients with confirmed urea cycle defects, particularly OTC 
deficiency, as compared to the normal population, it is unlikely that the wider range within 
the normal population will affect the ability to detect disease states.
There are multiple ways to implement either method into NBS workflows. First, laboratories 
could adopt the FIA–MS/MS stand-alone method for orotic acid quantification, which would 
necessitate a second sampling and analysis of the DBS specimen. Consideration could also 
be given to the use of the stand-alone method as a second tier test when traditional amino 
acid markers of the urea cycle (such as citrulline, glutamine, or arginine) are outside the 
normal range. Second, laboratories could simultaneously measure amino acids, 
acylcarnitines, and orotic acid using a methanol extraction and the combined FIA–MS/MS 
method with polarity switching.
The projected benefit from this research would be identification of patients with OTC 
deficiency through routine newborn screening however, before either assay can be 
implemented, the clinical utility needs to be demonstrated by the analysis of orotic acid in 
additional specimens from OTC deficient patients covering a range in clinical severity. 
Males affected with OTC deficiency can have a neonatal onset or present with a mild or late-
onset [21]. Likewise, the severity in carrier females depends on which mutation is present 
and on the proportion of hepatocytes expressing the mutant allele [22,23]. It is unknown 
whether orotic acid is elevated in the milder forms of the disease or in symptomatic carriers, 
especially within the first few days of life. It is also probable that orotic acid measurements 
in combination with existing amino acid markers and ratios may assist with the detection of 
these milder cases. Future studies will also include a more extensive evaluation of orotic acid 
concentrations within the presumptively normal newborn population for comparison to 
affected individuals.
Elevated orotic acid is not unique to OTC deficiency. Patients with hereditary orotic 
aciduria, HHH syndrome (hyperornithinemia–hyperammonemia–homocitrullinuria 
syndrome), lysinuric protein intolerance, and other urea cycle disorders such as ASS and 
ASL deficiencies have elevated orotic acid levels [1]. Orotic acid may also be elevated as a 
result of certain treatments, or physiologic conditions [7]. In newborn screening, differential 
diagnoses resulting from out-of-range analyte concentrations are not uncommon. Planned 
population based prospective studies followed by a clinical evaluation will help elucidate the 
sensitivity of this assay to detect patients with OTC deficiency and other treatable disorders 
associated with elevated orotic acid.
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In conclusion, this paper describes a high throughput assay quantifying orotic acid in DBS 
and demonstrates its compatibility with current FIA–MS/MS NBS assays for amino acids 
and acylcarnitines. Retrospective analysis of confirmed patient samples suggests a potential 
for the methods to identify patients with OTC deficiency, as well as other urea cycle defects.
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Total ion flow injection profile obtained by MRM of orotic acid and [1,3-15N2] orotic acid 
extracted from DBS specimens.
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Box–whisker plot of orotic acid concentration measured in DBS using the 2 described 
methods: stand-alone method (n = 1514) and the combined method (n = 516). The box 
corresponds to the 25th to the 75th percentile. The whiskers are the 1st to the 99th 
percentile.
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Comparison of analyte concentrations for 636 normal NBS specimens analyzed by the 
routine, non-derivatized method for amino acids and acylcarnitine analysis and the 
combined method which include orotic acid (*). The box corresponds to the 25th to the 75th 
percentile. The whiskers are the 1st to the 99th percentile.
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Table 2
Recovery of orotic acid from enriched DBS analyzed by both the stand-alone and combined methods.
Expected (μmol/l)
Stand-alone method (N = 25) Combined method (N = 50)
Obtained (μmol/l) %CV Obtained (μmol/l) %CV
1 1.05 11.2 0.89 21.4
10 7.41 3.6 8.18 9.9
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